scholarly journals Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials

2015 ◽  
Vol 3 (1) ◽  
pp. 27208 ◽  
Author(s):  
Istvan M. Majer ◽  
Fiona Gaughran ◽  
Christophe Sapin ◽  
Maud Beillat ◽  
Maarten Treur
Keyword(s):  
Clinical Trials ◽  
Maintenance Treatment ◽  
Randomized Clinical Trials ◽  
Mixed Treatment Comparison ◽  
Double Blind ◽  
Treatment Comparison ◽  
Mixed Treatment ◽  
Long Acting

Safety of Treatments for ADHD in Adults: Pairwise and Network Meta-Analyses

2017 ◽  
Vol 23 (2) ◽  
pp. 111-120 ◽  
Author(s):  
Danielly Chierrito de Oliveira ◽  
Patricia Guerrero de Sousa ◽  
Camila Borges dos Reis ◽  
Fernanda Stumpf Tonin ◽  
Laiza Maria Steimbach ◽  
...  
Keyword(s):  
Safety Profile ◽  
Odds Ratio ◽  
Extended Release ◽  
Controlled Trials ◽  
Mixed Treatment Comparison ◽  
Credibility Interval ◽  
Double Blind ◽  
Treatment Comparison ◽  
Mixed Treatment ◽  
Meta Analyses

Objective: The aim of the study was to analyze evidence comparing the profile of drugs used to treat ADHD in adult patients. Method: Systematic searches were conducted in electronic databases. Randomized, double-blind, parallel controlled trials that evaluated the safety of drugs in ADHD were included. The statistical analyses were conducted by pairwise meta-analyses and mixed treatment comparison (MTC). Results: Ten ( n = 3006) trials were included in the analyses. We observed statistical differences for the following outcomes: decreased appetite between atomoxetine and placebo (odds ratio [OR] = 0.15, 95% credibility interval [CrI] = [0.05, 0.38]) and extended-release mixed amphetamine salts and placebo (OR = 0.06, 95% CrI = [0.00, 0.51]); insomnia between atomoxetine and placebo (OR = 0.48, 95% CrI = [0.27, 0.88]) and extended-release mixed amphetamine salts and placebo (OR = 0.23, 95% CrI = [0.06, 0.76]); sleepiness between atomoxetine and methylphenidate OROS (OR = 0.24, 95% CrI = [0.06, 0.97]); and decreased libido between atomoxetine and placebo (OR = 0.28, 95% CrI = [0.08, 0.90]). Conclusion: It was possible to generate evidence about the safety profile of different ADHD drugs.

Drug Therapies for Patients with IgA Nephropathy: A Network Meta-analysis of Randomized Clinical Trials

2020 ◽  
Vol 15 (2) ◽  
pp. 132-144
Author(s):  
Kannan Sridharan ◽  
Gowri Sivaramakrishnan
Keyword(s):  
Clinical Trials ◽  
Iga Nephropathy ◽  
Outcome Measures ◽  
Randomized Clinical Trials ◽  
Angiotensin Receptor Blockers ◽  
Meta Analysis ◽  
Secondary Outcome ◽  
Mixed Treatment Comparison ◽  
Low Grade ◽  
Treatment Comparison

Background: Several drugs are used for treating IgA nephropathy (IgAN). We carried out a network meta-analysis evaluating these drugs. Methods: Electronic databases were searched for appropriate randomized clinical trials carried out in patients with IgAN. The primary outcome was proteinuria remission rates and there were several other secondary outcome measures. The risk of bias was assessed. Mixed treatment comparison estimates were modelled from direct and indirect comparison estimates. Grading of the evidence for key comparisons was carried out. Results: Fifty-seven clinical trials were included in the systematic review and 51 in the metaanalysis. Polyunsaturated fatty acids, corticosteroids/angiotensin receptor blockers (ARB), ARB, angiotensin converting enzyme inhibitors (ACEI), ARB/ACEI, corticosteroids/ACEI and hypolipidemics/ ARB were observed with significantly higher rates of proteinuria remission than the standard of care. Several benefits were observed with other drugs on the secondary outcome measures. A very low grade was observed for the interventions. Conclusion: We observed a few interventions to perform better in the management of IgAN. The results of this study will aid in further evaluation of such drugs that may assist in saving the resources and time. However, the readers should interpret the findings with great caution as the results might change with the advent of future head-to-head clinical trials.

Sign in / Sign up

Export Citation Format

Share Document